Core--Clinical
核心--临床
基本信息
- 批准号:6782230
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-11 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The clinical core provides comprehensive care for 248 children, teenagers, and young adults with sickle cell disease (SCD) followed in the pediatric sickle cell clinic and 132 adult patients followed in the adult clinic at University Hospital. The clinical care component of patient services is a system of high quality, readily available medical and psychosocial care that responds to the patient's needs. Our multi-disciplinary approach integrates the skills of medical subspecialists, social workers, counselors, psychologists, and nurses to meet the patient's and family's needs. The majority of the pediatric patients in this program are born in the Greater Cincinnati area and are identified by newborn screening program. The Cincinnati Comprehensive Sickle Cell
Center (CCSCC) continues to take a leadership role in insuring appropriate and timely follow-up for infants born in this area. Because of this, no baby born and screened in this area has been lost to follow-up. The clinical care component works effectively with the primary care provider and emphasizes a smooth transition into adult care. The clinical care component addresses educational, vocational and psychosocial aspects of patients with SCD. In addition, the clinical care component serves to promote both clinical and basic research that may benefit patients with SCD. The specific aims of the Clinical Core are 1). to provide comprehensive care to pediatric and adult patients with sickle cell disease (SCD), 2) to maintain a stable resource of patients for clinical and basic science research activities and to build, maintain and fully utilize an infrastructure which will provide the resources and support to conduct clinical research, 3) to provide training opportunities for residents, fellows, medical students, nursing students, as well as other health care professionals, and 4) to continue our already established collaborative relationship with the primary care physicians in the community and in the medical center to
ensure that all patients with sickle cell disease receive the benefits of a comprehensive program regardless of the managed care program in which they are enrolled.
临床核心为 248 名患有镰状细胞病 (SCD) 的儿童、青少年和年轻人提供全面护理,这些患者在儿科镰状细胞病诊所进行随访,并在大学医院的成人诊所进行了 132 名成人患者的随访。患者服务的临床护理部分是一个高质量、随时可用的医疗和社会心理护理系统,可满足患者的需求。我们的多学科方法整合了医学专家、社会工作者、咨询师、心理学家和护士的技能,以满足患者和家人的需求。该计划中的大多数儿科患者出生在大辛辛那提地区,并通过新生儿筛查计划进行识别。辛辛那提综合镰状细胞
中心 (CCSCC) 继续发挥领导作用,确保对该地区出生的婴儿进行适当和及时的随访。因此,在该领域出生和筛查的婴儿都没有失访。临床护理部分与初级保健提供者有效合作,并强调顺利过渡到成人护理。临床护理部分涉及 SCD 患者的教育、职业和心理社会方面。此外,临床护理部分还致力于促进可能使 SCD 患者受益的临床和基础研究。临床核心的具体目标是 1)。为患有镰状细胞病(SCD)的儿科和成人患者提供全面的护理,2)为临床和基础科学研究活动维持稳定的患者资源,并建立、维护和充分利用能够提供资源和支持的基础设施进行临床研究,3) 为住院医师、研究员、医学生、护理学生以及其他医疗保健专业人员提供培训机会,以及 4) 继续我们与社区和社区的初级保健医生已经建立的合作关系医疗中心至
确保所有镰状细胞病患者都能获得综合计划的好处,无论他们参加的管理式医疗计划如何。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAREN A KALINYAK其他文献
KAREN A KALINYAK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAREN A KALINYAK', 18)}}的其他基金
DIPYRIDAMOLE/MAGNESIUM TO IMPROVE SICKLE CELL HYDRATION
双嘧达莫/镁改善镰状细胞水合作用
- 批准号:
7607766 - 财政年份:2007
- 资助金额:
$ 10万 - 项目类别:
Dipyridamole/Magnesium to Improve Sickle Cell Hydration
双嘧达莫/镁改善镰状细胞水合作用
- 批准号:
6782210 - 财政年份:2003
- 资助金额:
$ 10万 - 项目类别:
MANAGEMENT OF SICKLE CELL VASO-0CCLUSIVE EPISODES
镰状细胞 VASO-0 闭塞性发作的处理
- 批准号:
6584668 - 财政年份:2002
- 资助金额:
$ 10万 - 项目类别:
MANAGEMENT OF SICKLE CELL VASO-0CCLUSIVE EPISODES
镰状细胞 VASO-0 闭塞性发作的处理
- 批准号:
6667541 - 财政年份:2002
- 资助金额:
$ 10万 - 项目类别:
MANAGEMENT OF SICKLE CELL VASO-0CCLUSIVE EPISODES
镰状细胞 VASO-0 闭塞性发作的治疗
- 批准号:
6456258 - 财政年份:2001
- 资助金额:
$ 10万 - 项目类别:
MANAGEMENT OF SICKLE CELL VASO-0CCLUSIVE EPISODES
镰状细胞 VASO-0 闭塞性发作的治疗
- 批准号:
6325980 - 财政年份:2000
- 资助金额:
$ 10万 - 项目类别:
相似海外基金
Washington Obstetric-Fetal Pharmacology Research Unit
华盛顿产胎儿药理学研究单位
- 批准号:
7695403 - 财政年份:2004
- 资助金额:
$ 10万 - 项目类别: